HOME >> BIOLOGY >> NEWS
A Versatile Signal In Vertebrate Embryogenesis: Wnt-4 Regulates Kidney Development, Sex Organ Differentiation, Neuronal Survival And Axonal Guidance

Researchers at the Max Planck Institute for Immunobiology, at Harvard University, at Oulu University /Finland and at the University of California characterised the important signalling role of a secreted protein of the Wnt family in kidney development, sex organ differentiation and axonal growth and guidance in vertebrate embryogenesis. (Development 125, 4225-4234, 1998; Nature 397, 405-409, 1999; Science 283, 1180-1183,1999)

The formation of vertebrate organs is a complex process. It is characterised by the interaction of different cells and tissues to assure the concerted program of cell growth, differentiation and morphogenesis which garanties the functional architecture of the adult organ. Cell and tissue interactions are mediated by signalling molecules of various protein classes.

The mammalian kidney has been widely exploited as a model system to study the principles of vertebrate organ formation. Kidney development is characterized by an interaction between an epithelial and a mesenchymal compartment: the Wolffian duct and the nephrogenic mesenchyme. Dependent on signals from the mesenchyme, the ureter will give rise to the adult collecting duct system whereas the mesenchyme upon signals from the ureter will differentiate to form the major part of the nephrons, the functional unit of the excretory system, which is responsible for removal of nitrogenous waste and physiological control of salt balance.

An important family of signalling molecules is encoded by Wnt genes. Wnt proteins are secreted glycoproteins which have been shown to regulate numerous developmental processes like brain formation, limb patterning, and axis formation in the vertebrate embryo.

Classical experiments demonstrated the reciprocal nature of inductive events in the kidney using tissue separation and recombination techniques. The ureteric bud induces the mesenchyme to condense and to form tubules - precursors to nephrons. The mesenchyme in turn promotes ureteric bud
'"/>

Contact: Andreas Kispert
kispert@immunbio.mpg.de
49-76-1-51-08-4
Max-Planck-Gesellschaft
2-Mar-1999


Page: 1 2 3

Related biology news :

1. Versatile immunosuppressant drug may have new role in radiotherapy for cancer
2. Epilepsy: Signals brake in brain impaired
3. Signal chemical primes plants for pest attack
4. Reproductive Signals Affect Lifespan In Roundworm C. Elegans, Offering Possible Insight Into Human Aging Process
5. Small G-Proteins Make A Big Difference -- Nerve Cell Signalling Is Regulated By Arf-GTPases And Their Activators
6. How Nerve Cells Get In Touch - A Molecular Model Of Synapse Formation And Retrograde Signalling In The Brain
7. Cell Suicide Prevented By Survival Signals
8. Plant-Based Fat Inhibits Cancer-Cell Growth By Enhancing Cells Signaling System, UB Researchers Show
9. Toxic Protein That Interferes With Brain Signals May Trigger Onset Of Alzheimers Disease
10. R-Type Channels - A New Type Of Calcium Channels Controlling Signal Transduction Between Neurons In The Brain
11. Cholesterol Anchor Helps Signaling Proteins Direct Development

Post Your Comments:
(Date:5/21/2013)... occur in the body, stem cells in the ... differentiating into mature immune cells that can fight ... deplete these cell populations, potentially leading to the ... Now, a team of researchers led by biologists ... found that, in mouse models, the molecule microRNA-146a ...
(Date:5/21/2013)... University researchers have developed a new method for ... holes in the cell surface. The technique could ... related biological fields. , Bulk electroporation a ... reversible nanopores in the cell membrane that are ... is an increasingly popular method of cell transfection. ...
(Date:5/21/2013)... new University of Michigan Water Center today awarded ... Great Lakes restoration and protection efforts. , The ... diverse projects, including efforts to track the remediation ... techniques to control non-native weedy plant invasions; study ... fish responses to restoration activities. , The grants ...
Breaking Biology News(10 mins):Keeping stem cells strong 2Single-cell transfection tool enables added control for biological studies 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4
(Date:5/21/2013)... Wisc. (PRWEB) May 21, 2013 ... parts distributor , will be exhibiting for the ... Advancement of Medical Instrumentation (AAMI) 2013 Conference and ... purchase, support, distribute, and manufacture healthcare technologies. This ... in Long Beach, California. , The three-day ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... Canada (PRWEB) May 21, 2013 ... is a strong push within the industry to ... and Manufacturing Organizations and pharma companies often means ... frames. , Microtablets, developed in collaboration with Sensidose ... effective outsourcing can bring products to market sooner. ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: